---
title: "HCW Biologics director Scott T. Garrett acquires 7,736 common shares for $19,995.56"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294550269.md"
description: "HCW Biologics director Scott T. Garrett acquired 7,736 common shares at $2.59 each via Garrett Capital Partners for a total of $19,995.56. This transaction increased his indirect stake held through the LLC to 41,644 shares."
datetime: "2026-07-31T20:02:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294550269.md)
  - [en](https://longbridge.com/en/news/294550269.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294550269.md)
generator: "portal-rs"
---

# HCW Biologics director Scott T. Garrett acquires 7,736 common shares for $19,995.56

-   HCW Biologics director Scott T. Garrett reported buying 7,736 common shares at USD 2.59 each through Garrett Capital Partners. \* Indirect stake held via the LLC rose to 41,644 shares following the purchase. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-035619), on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [HCWB.US](https://longbridge.com/en/quote/HCWB.US.md)

## Related News & Research

- [HCW Biologics says Q1 2026 financials cannot be relied on due to EPS misstatement](https://longbridge.com/en/news/295965944.md)
- [HCW Biologics restates Q1 EPS, cutting net income attributable to common shareholders by USD 728,000](https://longbridge.com/en/news/295966539.md)
- [HCWB: Positive clinical data, higher licensing revenue, and new equity funding offset by net loss and funding risks](https://longbridge.com/en/news/295967027.md)
- [HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results | HCWB Stock News](https://longbridge.com/en/news/295966778.md)
- [LG Electronics deepens robotics collaboration with Nvidia](https://longbridge.com/en/news/296171747.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**